A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS ACS 2-TIMI 51; ATLAS-2-TIMI-51; ATLAS-ACS-2-TIMI-51
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 09 Aug 2017 This trail is dicontinued in Belgium as Eudra.
    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 17 Nov 2013 Results of an analysis investigating the effects of proton pump inhibitor use in stratum 2 (n=2203) presented at the 86th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top